Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Current Assets (2021 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed Current Assets for 5 consecutive years, with $284.9 million as the latest value for Q4 2025.

  • Quarterly Current Assets fell 14.78% to $284.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $284.9 million through Dec 2025, down 14.78% year-over-year, with the annual reading at $284.9 million for FY2025, 14.78% down from the prior year.
  • Current Assets hit $284.9 million in Q4 2025 for ARS Pharmaceuticals, down from $338.9 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $378.3 million in Q1 2021 to a low of $60.7 million in Q4 2021.
  • Historically, Current Assets has averaged $268.9 million across 5 years, with a median of $269.1 million in 2022.
  • Biggest YoY gain for Current Assets was 357.27% in 2022; the steepest drop was 30.93% in 2022.
  • Year by year, Current Assets stood at $60.7 million in 2021, then surged by 357.27% to $277.7 million in 2022, then decreased by 16.56% to $231.7 million in 2023, then skyrocketed by 44.26% to $334.3 million in 2024, then decreased by 14.78% to $284.9 million in 2025.
  • Business Quant data shows Current Assets for SPRY at $284.9 million in Q4 2025, $338.9 million in Q3 2025, and $281.4 million in Q2 2025.